港股异动 | 医药股多数走高行业近期迎来多项催化机构看好板块进一步修复空间

智通财经10-17

智通财经APP获悉，医药股多数走高，截至发稿，来凯医药-B(02105)涨32.9%，报8.2港元；宜明昂科-B(01541)涨21.93%，报6.06港元；亚盛医药-B(06855)涨6.31%，报47.2港元；再鼎医药(09688)涨4.57%，报20.35港元。消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。据国投证券，本次医保谈判中共有约41个国产独家创新药（含引进）通过形式审查，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2476163976?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-17 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476163976","market":"hk","top_or_hot":-1,"title":"港股异动 | 医药股多数走高 行业近期迎来多项催化 机构看好板块进一步修复空间","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，医药股多数走高，截至发稿，来凯医药-B(02105)涨32.9%，报8.2港元；宜明昂科-B(01541)涨21.93%，报6.06港元；亚盛医药-B(06855)涨6.31%，报47.2港元；再鼎医药(09688)涨4.57%，报20.35港元。消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。据国投证券，本次医保谈判中共有约41个国产独家创新药（含引进）通过形式审查，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1195217.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 医药股多数走高 行业近期迎来多项催化 机构看好板块进一步修复空间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 医药股多数走高 行业近期迎来多项催化 机构看好板块进一步修复空间\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-17 13:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1195217.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，医药股多数走高，截至发稿，来凯医药-B(02105)涨32.9%，报8.2港元；宜明昂科-B(01541)涨21.93%，报6.06港元；亚盛医药-B(06855)涨6.31%，报47.2港元；再鼎医药(09688)涨4.57%，报20.35港元。消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。据国投证券，本次医保谈判中共有约41个国产独家创新药（含引进）通过形式审查，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1195217.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1195217.html","article_id":"2476163976","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476163976","pubTimestamp":1729144067,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。该行认为，国谈进入常态化阶段，创新药长期放量可期。建议以最终品种名单为准。近期医药板块在市场投资情绪波动下大幅震荡，但考虑到此前板块估值已处于历史底部，该行认为仍有进一步修复空间。中泰证券表示，展望下半年，全链条支持创新药、设备更新换代、基药目录等有望持续推进；医保谈判、ESMO/WCLC/ASH/美国眼科学会年会等创新药领域重大会议、GLP-1研发推进等有望形成催化。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","09688":"再鼎医药","BK1515":"抗疫概念","01541":"宜明昂科-B","BK1161":"生物科技","02105":"来凯医药-B","BK1574":"生物医药B类股","09939":"开拓药业-B","06855":"亚盛医药-B","BK1588":"回港中概股"},"translate_title":"Hong Kong stocks have changed, most pharmaceutical stocks have risen, the industry has recently ushered in a number of catalysts, institutions are optimistic about the further repair space of the sector","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"01541":0.9,"02105":0.9,"06855":0.9,"09688":0.9},"content_text":"智通财经APP获悉，医药股多数走高，截至发稿，来凯医药-B(02105)涨32.9%，报8.2港元；宜明昂科-B(01541)涨21.93%，报6.06港元；亚盛医药-B(06855)涨6.31%，报47.2港元；再鼎医药(09688)涨4.57%，报20.35港元。消息面上，目前2024年医保谈判即将进入谈判/竞价阶段。据国投证券，本次医保谈判中共有约41个国产独家创新药（含引进）通过形式审查，有望新增药品谈判：包括2023年7月1日至2024年6月30日之间新获批上市的28个创新药，以及2023年7月1日以前获批上市的13个创新药。该行认为，国谈进入常态化阶段，创新药长期放量可期。交银国际指，第十批药品国采报量文件显示，此轮国采入围门槛历史最高、注射剂占比历史最高，预计竞争将异常激烈，但对大多数处方药企来说，涉及大品种较少，影响或许有限。建议以最终品种名单为准。近期医药板块在市场投资情绪波动下大幅震荡，但考虑到此前板块估值已处于历史底部，该行认为仍有进一步修复空间。中泰证券表示，展望下半年，全链条支持创新药、设备更新换代、基药目录等有望持续推进；医保谈判、ESMO/WCLC/ASH/美国眼科学会年会等创新药领域重大会议、GLP-1研发推进等有望形成催化。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476163976"}

港股异动 | 医药股多数走高 行业近期迎来多项催化 机构看好板块进一步修复空间

精彩评论

港股异动 | 医药股多数走高行业近期迎来多项催化机构看好板块进一步修复空间